haloperidol has been researched along with MPTP Neurotoxicity Syndrome in 10 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol has recently been found to be metabolized to its pyridinium ion (HP+)." | 5.29 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. ( Fang, J; Yu, PH; Zuo, D, 1995) |
| "This is a review of reserpine, haloperidol, and various phenothiazines that produce parkinsonism and other movement disorders." | 4.78 | Drug-induced parkinsonism and other movement disorders. ( Ross, RT, 1990) |
| "Pretreatment with haloperidol suppressed both the antiparkinsonian effects and the hyperactivity induced by apomorphine." | 1.29 | Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. ( Akai, T; Kuno, S; Mizuta, E; Yamaguchi, M, 1993) |
| "Haloperidol has recently been found to be metabolized to its pyridinium ion (HP+)." | 1.29 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. ( Fang, J; Yu, PH; Zuo, D, 1995) |
| " In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra." | 1.29 | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. ( Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotliarova, A | 2 |
| Podturkina, AV | 2 |
| Pavlova, AV | 2 |
| Gorina, DS | 2 |
| Lastovka, AV | 2 |
| Ardashov, OV | 2 |
| Rogachev, AD | 2 |
| Izyurov, AE | 2 |
| Arefieva, AB | 2 |
| Kulikov, AV | 2 |
| Tolstikova, TG | 2 |
| Volcho, KP | 2 |
| Salakhutdinov, NF | 2 |
| Sidorova, Y | 2 |
| Mihara, T | 1 |
| Mihara, K | 1 |
| Yarimizu, J | 1 |
| Mitani, Y | 1 |
| Matsuda, R | 1 |
| Yamamoto, H | 1 |
| Aoki, S | 1 |
| Akahane, A | 1 |
| Iwashita, A | 1 |
| Matsuoka, N | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Richard, MG | 1 |
| Bennett, JP | 1 |
| Akai, T | 1 |
| Yamaguchi, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Fang, J | 1 |
| Zuo, D | 1 |
| Yu, PH | 1 |
| Doucet, JP | 1 |
| Nakabeppu, Y | 1 |
| Bedard, PJ | 1 |
| Hope, BT | 1 |
| Nestler, EJ | 1 |
| Jasmin, BJ | 1 |
| Chen, JS | 1 |
| Iadarola, MJ | 1 |
| St-Jean, M | 1 |
| Wigle, N | 1 |
| Blanchet, P | 1 |
| Grondin, R | 1 |
| Robertson, GS | 1 |
| Lawrence, MS | 1 |
| Redmond, DE | 1 |
| Ross, RT | 1 |
| Weihmuller, FB | 1 |
| Hadjiconstantinou, M | 1 |
| Bruno, JP | 1 |
| Neff, NH | 1 |
1 review available for haloperidol and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Drug-induced parkinsonism and other movement disorders.
Topics: Haloperidol; Humans; Movement Disorders; MPTP Poisoning; Parkinson Disease, Secondary; Phenothiazine | 1990 |
9 other studies available for haloperidol and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Aminopyridines; Ani | 2007 |
Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denerva | 2007 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1994 |
Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Topics: Aggression; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Haloperid | 1993 |
Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Line; Dose- | 1995 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Str | 1996 |
MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys.
Topics: Animals; Apomorphine; Blinking; Chlorocebus aethiops; Dopamine Agents; Haloperidol; Male; MPTP Poiso | 1991 |
Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: Animals; Brain Diseases; Catalepsy; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; G(M1) Gangl | 1989 |